Stocks · Healthcare · Biotechnology
Neurocrine Biosciences, Inc. NBIX
$143.18 +1.76% Close, Oct 2, 2026 · NASDAQ · Market cap $14.40B
Strong growthHigh qualityInexpensive vs sectorLow risk
Next earnings report: Oct 27, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $6.82, up 101.8% year over year.
- The shares trade at 21.0× trailing earnings, lower than 95% of the company's own readings over the past five years.
- Revenue over the last four quarters was $3.37B, up 34.4% from a year earlier, accelerating from 28.6% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 23%
- EPS growth (TTM, YoY)Top 13%
- FCF growth (TTM, YoY)Top 23%
- Revenue growth, 3-year CAGRTop 26%
- Revenue growth accelerationTop 16%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 11%
- Gross marginTop 9%
- Operating marginTop 10%
- Cash conversion (OCF / net income)Bottom 34%
- Accruals (lower is better)Bottom 32%
- Net debt / EBITDA (lower is better)Top 38%
- Interest coverTop 2%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 11%
- Free-cash-flow yieldTop 15%
- EBITDA / enterprise valueTop 19%
- Sales / enterprise valueTop 49%
- P/E vs own 5-year history (lower is better)Top 15%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 46%
- 6-month returnTop 48%
- 1-year return vs S&P 500Bottom 45%
- Distance from 52-week highTop 36%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 24%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 32%
- Upside to consensus price targetBottom 41%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 16%
- Maximum drawdown, 3 yearsTop 16%
- Beta vs S&P 500 (lower is better)Top 21%
- Net debt / EBITDA (lower is better)Top 38%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 28.6% | 34.4% | ↑ |
| EPS growth (YoY) | 120.0% | 101.8% | ↓ |
| Gross margin | 98.5% | 98.0% | ↓ |
| Operating margin | 19.7% | 23.4% | ↑ |
| FCF margin | 21.1% | 25.8% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 34.4% | 28.6% | ↑ | Top 23% |
| EPS growth (TTM, YoY) | 101.8% | 120.0% | ↓ | Top 13% |
| Gross margin | 98.0% | 98.5% | ↓ | Top 9% |
| Operating margin | 23.4% | 19.7% | ↑ | Top 10% |
| Net margin | 20.9% | 13.9% | ↑ | — |
| Free-cash-flow margin | 25.8% | 21.1% | ↑ | — |
| Return on invested capital | 13.2% | — | Top 11% | |
| Revenue growth, 3-year CAGR | 24.3% | — | Top 26% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.27×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -3.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +14.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 0.08×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 272.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.87%
- Shareholder yield
- -0.87%
- Share count change, 1 year
- +3.2%
- Share count change, 3-year CAGR
- +1.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 31, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +19.2%
- Average 2-day reaction, last 8
- +1.3%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $204.18
- Target vs current price
- +42.6%
- Analysts with a rating
- 37
- Share rating Buy or Strong Buy
- 86%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -15.8% | +2.6% | -10.7% | -13.4% | — |
| May 5, 2026 | +59.0% | +0.7% | +12.3% | +15.5% | +38.4% |
| Feb 11, 2026 | +4.4% | -0.2% | -6.7% | -5.9% | +8.7% |
| Oct 28, 2025 | +29.1% | -1.0% | -4.7% | -5.2% | -8.6% |
| Jul 30, 2025 | +8.2% | +1.9% | -4.3% | +2.0% | +5.4% |
| May 5, 2025 | -85.0% | +0.1% | +5.5% | +13.6% | +24.7% |
| Feb 6, 2025 | -38.3% | -0.5% | -22.5% | -25.5% | -27.5% |
| Oct 30, 2024 | -17.9% | +7.0% | +4.6% | +10.1% | +29.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $1.39 | $1.65 | -15.8% | $959.0M |
| May 5, 2026 | $1.94 | $1.22 | +59.0% | $814.5M |
| Feb 11, 2026 | $1.88 | $1.80 | +4.4% | $805.5M |
| Oct 28, 2025 | $2.04 | $1.58 | +29.1% | $794.9M |
| Jul 30, 2025 | $1.06 | $0.98 | +8.2% | $687.5M |
| May 5, 2025 | $0.08 | $0.54 | -85.0% | $572.6M |
| Feb 6, 2025 | $1.00 | $1.62 | -38.3% | $627.7M |
| Oct 30, 2024 | $1.24 | $1.51 | -17.9% | $622.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 21.0× | 40.5× | 5th | Top 11% |
| P/E (forward) | 20.3× | — | — | — |
| EV / EBITDA | 15.8× | — | — | Top 19% |
| EV / Sales | 4.29× | — | — | Top 49% |
| Free-cash-flow yield | 6.05% | — | — | Top 15% |
| Earnings yield | 4.76% | — | — | Top 11% |
P/E over the past five years
Range 20.8× – 208.3× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +4.5%
- Earnings per share growth (TTM)
- +101.8%
- Change in P/E multiple
- -39.5%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.3%
- 200-day average slope (20 days)
- -0.1%
- Distance from 50-day average
- -8.0%
- Distance from 200-day average
- -2.8%
- RSI (14)
- 41.2
- Relative volume
- 1.27×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 35.0%
- Volatility vs own 5-year history
- 73th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.60
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -22.8%
- Maximum drawdown, 3 years
- -42.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 30, 2025 | Apr 8, 2025 | -42.9% | 47 days | 146 days (Nov 5, 2025) |
| Jan 25, 2021 | Jan 27, 2022 | -39.3% | 255 days | 193 days (Nov 2, 2022) |
| Nov 30, 2022 | May 31, 2023 | -29.5% | 124 days | 143 days (Dec 22, 2023) |
| Aug 1, 2024 | Oct 9, 2024 | -27.1% | 48 days | 76 days (Jan 30, 2025) |
| Jul 30, 2026 | Sep 29, 2026 | -25.4% | 42 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $14.40B
- P/E (TTM)
- 21.0
- EPS, diluted (TTM)
- $6.82
- Revenue (TTM)
- $3.37B
- 52-week range
- $122.14 – $186.12
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Gross profit | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| Operating income | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| Net income | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| EPS (diluted) | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $622.1M | $627.7M | $572.6M | $687.5M | $794.9M | $805.5M | $814.5M | $959.0M |
| Net income | $129.8M | $103.1M | $7.9M | $107.5M | $209.5M | $153.7M | $197.9M | $144.4M |
| EPS (diluted) | $1.24 | $1.00 | $0.08 | $1.06 | $2.04 | $1.48 | $1.91 | $1.39 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $256.5M | $339.4M | $389.9M | $595.4M | $782.7M |
| Capital expenditure | -$23.4M | -$16.5M | -$28.3M | -$38.2M | -$34.0M |
| Free cash flow | $233.1M | $322.9M | $361.6M | $557.2M | $748.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $27.5M | $44.7M | $65.3M | -$177.9M | -$38.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $389.8M
- Total assets
- $5.36B
- Total liabilities
- $1.67B
- Total debt
- $401.8M
- Net debt
- $69.4M
- Shareholders’ equity
- $3.69B
As of Jun 30, 2026 (filed Jul 31, 2026).
Short interest
- Shares sold short
- 4,964,907
- Days to cover
- 5.37
- Change vs previous report
- -1.8%
FINRA short interest, settlement date Sep 15, 2026.